Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer

http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2234975

BEGIN Berkeley Gateway to Innovation
portal to the UC Berkeley entrepreneurship community

Join the IPIRA Mailing List

Read the IPIRA Newsletter

Accessibility | Nondiscrimination | Privacy

© 2022 Regents of the University of California. All Rights Reserved.